SCHEMBL5567700

SCHEMBL5567700

Cc1nc2c3c(c(C(=O)N4CCCC4)cn2c1C)CCC(c1ccccc1)C3

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPR P35270 3/20 0.41
CYP3A4 P08684 2/20 0.40
CYP2C9 P11712 2/20 0.40
RIPK1 Q13546 3/20 0.39
F11 P03951 1/20 0.38
HCAR2 Q8TDS4 1/20 0.37
FASN P49327 1/20 0.37
ALDH1A1 P00352 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
LMNA P02545 1/20 0.36
GLA P06280 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HSD11B1 P28845 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5568619 0.91 ALDH1A1 (0.42) SPRCYP3A4CYP2C9FASNALDH1A1
SCHEMBL5564813 0.89 HCAR2 (0.43) SPRCYP3A4CYP2C9RIPK1HCAR2
SCHEMBL5567085 0.87 CYP3A4 (0.41) CYP3A4CYP2C9RIPK1HCAR2KDM4E
SCHEMBL5567457 0.85 CYP3A4 (0.40) SPRCYP3A4CYP2C9RIPK1HCAR2
SCHEMBL5564848 0.85 CYP3A4 (0.40) CYP3A4CYP2C9RIPK1HCAR2ALDH1A1
SCHEMBL5567092 0.83 CYP3A4 (0.39) CYP3A4CYP2C9HCAR2ALDH1A1KDM4E
SCHEMBL4599450 0.80 CYP3A4 (0.60) SPRCYP3A4CYP2C9RIPK1F11
SCHEMBL4599571 0.80 CYP3A4 (0.60) SPRCYP3A4CYP2C9RIPK1F11
SCHEMBL5567826 0.79 CYP3A4 (0.42) CYP3A4CYP2C9HCAR2MEN1KMT2A
SCHEMBL5567838 0.78 CYP3A4 (0.41) CYP3A4CYP2C9RIPK1HCAR2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070203114-A1 7,8,9,10-Tetrahydro-Imidazo [2,1-A] Isochinolines ALTANA PHARMA AG (DE) 2007-08-30 US disclosed
EP-1805173-A2 7, 8, 9, 10- TETRAHYDRO-IMIDAZO [2,1-A] ISOQUINOLINE DERIVATIVES AND THEIR USE AS GASTRIC ACID SECRETION INHIBITORS Altana Pharma AG (DE) 2007-07-11 EP disclosed
WO-2005090346-A2 7, 8, 9, 10- TETRAHYDRO-IMIDAZO [2,1-A] ISOQUINOLINE DERIVATIVES AND THEIR USE AS GASTRIC ACID SECRETION INHIBITORS ALTANA PHARMA AG (DE) 2005-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203114-A1 7,8,9,10-Tetrahydro-Imidazo [2,1-A] Isochinolines GIPR, CCKBR, SLC10A2 SPR 4233/4885CYP3A4 292/4885CYP2C9 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.